The researchers observed these endpoints according to degree of LDL cholesterol reduction after 1 month of treatment.
Compared with CABG, PCI was associated with similar risks of all-cause mortality, and with elevated risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization.
Researchers concluded that the use of statins is the likely cause of this diagnosis appearing to be beneficial against breast cancer development and subsequent death.
After adjusting for age and gender, patients randomized to the aggressive treatment arm demonstrated triple the risk of mortality from any cause vs. patients who received less intense treatment (4.9% vs. 1.7%, hazard ratio [HR] 3.12, 95% CI: 1.00-9.69; P=0.012).
Several sub-studies investigated the superior efficacy of spironolactone in RHTN and whether there was potential benefit with amiloride in the same population.
MRAs such as spironolactone and eplerenone are "still underused in routine clinical practice" but can be effective in countering the harms of high aldosterone levels, explained study author Professor Farzin Beygui, MD, PhD.
Researchers enrolled patients with ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving a potent P2Y12 inhibitor to receive bivalirudin or heparin during PCI.
The PRECISION-ABPM study included 444 patients (408 with osteoarthritis; 36 RA) who had evidence of, or were at increased risk for, coronary artery disease.
The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.